Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Allergan will pay $60 million up front to acquire RetroSense Therapeutics, which is developing gene therapies to restore sight in people with eye diseases. With the deal, Allergan gains access to RST-001, a gene therapy being tested in a Phase I/II study against retinitis pigmentosa, a rare disease marked by peripheral vision loss, night vision challenges, and eventual blindness. RST-001 delivers a gene called channelrhodopsin-2 that may allow new photosensors to be created in retinal ganglion cells.
This article has been sent to the following recipient: